title: Locally advanced prostate cancer: a population-based study of treatment patterns.
abstract: Study Type--Therapy (practice patterns). Level of Evidence 2b. What's known on the subject? And what does the study add? The treatment of locally advanced prostate cancer varies widely even though there is level one evidence supporting the use of multimodality therapy as compared with monotherapy. This study defines treatment patterns of locally advanced prostate cancer within the United States and identifies predicators of who receives multimodality therapy rather than monotherapy.
  
  
  OBJECTIVE
  • To identify treatment patterns and predictors of receiving multimodality therapy in patients with locally advanced prostate cancer (LAPC).
  
  
  METHODS
  • The cohort comprised patients ≥66 years with clinical stage T3 or T4 non-metastatic prostate cancer diagnosed between 1998 and 2005 identified from the Surveillance, Epidemiology and End Results (SEER) cancer registry records linked with Medicare claims. • Treatments were classified as radical prostatectomy (RP), radiation therapy (RT) and androgen deprivation therapy (ADT) received within 6 and 24 months of diagnosis. • We assessed trends over time and used multivariable logistic regression to identify predictors of multimodality treatment.
  
  
  RESULTS
  • Within the first 6 months of diagnosis, 1060 of 3095 patients (34%) were treated with a combination of RT and ADT, 1486 (48%) received monotherapy (RT alone, ADT alone or RP alone), and 461 (15%) received no active treatment. • The proportion of patients who received RP increased, exceeding 10% in 2005. • Use of combined RT and ADT and use of ADT alone fluctuated throughout the study period. • In all 6% of patients received RT alone in 2005. • Multimodality therapy was less common in patients who were older, African American, unmarried, who lived in the south, and who had co-morbidities or stage T4 disease.
  
  
  CONCLUSIONS
  • Treatment of LAPC varies widely, and treatment patterns shifted during the study period. • The slightly increased use of multimodality therapy since 2003 is encouraging, but further work is needed to increase combination therapy in appropriate patients and to define the role of RP.
authors.affiliation: Department of Surgery, Division of Urology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA. will.lowrance@hci.utah.edu
authors.forename: William T
authors.initials: WT
authors.lastname: Lowrance
authors.forename: Elena B
authors.initials: EB
authors.lastname: Elkin
authors.forename: David S
authors.initials: DS
authors.lastname: Yee
authors.forename: Andrew
authors.initials: A
authors.lastname: Feifer
authors.forename: Behfar
authors.initials: B
authors.lastname: Ehdaie
authors.forename: Lindsay M
authors.initials: LM
authors.lastname: Jacks
authors.forename: Coral L
authors.initials: CL
authors.lastname: Atoria
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Zelefsky
authors.forename: Howard I
authors.initials: HI
authors.lastname: Scher
authors.forename: Peter T
authors.initials: PT
authors.lastname: Scardino
authors.forename: James A
authors.initials: JA
authors.lastname: Eastham
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000600:supply & distribution* / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000379:methods / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D011468:Prostatectomy / Q000706:statistics & numerical data*; D011471:Prostatic Neoplasms / Q000628:therapy*; D011878:Radiotherapy / Q000706:statistics & numerical data*; D018426:SEER Program / Q000706:statistics & numerical data; D014481:United States
chemical_list: D000726:Androgen Antagonists
references.citation: Lancet. 2002 Jul 13;360(9327):103-6
references.pmid: 12126818
references.citation: J Urol. 2009 Mar;181(3):956-62
references.pmid: 19167731
references.citation: BJU Int. 2010 Jan;105(2):185-90
references.pmid: 19594741
references.citation: J Clin Oncol. 2003 Nov 1;21(21):3972-8
references.pmid: 14581419
references.citation: J Clin Oncol. 2010 Mar 20;28(9):1508-13
references.pmid: 20159826
references.citation: JAMA. 2006 Nov 15;296(19):2329-35
references.pmid: 17105795
references.citation: Med Care. 2002 Aug;40(8 Suppl):IV-3-18
references.pmid: 12187163
references.citation: Cancer. 2006 Jun 15;106(12):2603-9
references.pmid: 16700037
references.citation: J Urol. 2008 Dec;180(6):2409-13; discussion 2414
references.pmid: 18930270
references.citation: J Clin Epidemiol. 2000 Dec;53(12):1258-67
references.pmid: 11146273
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1117-23
references.pmid: 20124165
references.citation: N Engl J Med. 1997 Jul 31;337(5):295-300
references.pmid: 9233866
references.citation: J Clin Oncol. 2008 Feb 1;26(4):585-91
references.pmid: 18172188
references.citation: Cancer Chemother Pharmacol. 1997;40(4):321-9
references.pmid: 9225950
references.citation: BJU Int. 2006 Aug;98(2):335-40
references.pmid: 16879674
references.citation: Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90
references.pmid: 15817329
references.citation: Mol Urol. 1999;3(3):253-260
references.pmid: 10851331
references.citation: Lancet. 2005 Aug 13-19;366(9485):572-8
references.pmid: 16099293
references.citation: Lancet Oncol. 2006 Jun;7(6):472-9
references.pmid: 16750497
references.citation: Am J Public Health. 2001 Jan;91(1):126-8
references.pmid: 11189804
references.citation: BJU Int. 2005 Apr;95(6):751-6
references.pmid: 15794776
references.citation: Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1243-52
references.pmid: 11483335
references.citation: Lancet. 2009 Jan 24;373(9660):301-8
references.pmid: 19091394
references.citation: J Urol. 2001 Aug;166(2):500-6; discussion 506-7
references.pmid: 11458055
references.citation: Cancer. 2008 May 15;112(10):2195-201
references.pmid: 18393326
references.citation: Ann Surg Oncol. 2006 Aug;13(8):1021-34
references.pmid: 16897272
references.citation: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references.pmid: 20610543
references.citation: JAMA. 2008 Jan 23;299(3):289-95
references.pmid: 18212313
references.citation: J Urol. 2006 Aug;176(2):564-8
references.pmid: 16813890